Avalo Therapeutics Inc
NASDAQ:AVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avalo Therapeutics Inc
Selling, General & Administrative
Avalo Therapeutics Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
Selling, General & Administrative
-$22.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$14B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$5.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.8B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$3.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-15%
|
|
Avalo Therapeutics Inc
Glance View
Avalo Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 42 full-time employees. The company went IPO on 2015-11-13. The firm discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.
See Also
What is Avalo Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-22.9m
USD
Based on the financial report for Dec 31, 2025, Avalo Therapeutics Inc's Selling, General & Administrative amounts to -22.9m USD.
What is Avalo Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-18%
Over the last year, the Selling, General & Administrative growth was -33%. The average annual Selling, General & Administrative growth rates for Avalo Therapeutics Inc have been -3% over the past three years , -3% over the past five years , and -18% over the past ten years .
